On October 29, Tianjin Pharmaceutical Group Co., Ltd. issued an announcement stating that its subsidiaries, Tianjin Pharmaceutical Heping and Hubei Tianjin Pharmaceutical, participated in the 11th batch of national centralized drug procurement organized by the National Joint Procurement Office for Drugs. Seven products, namely Betamethasone Sodium Phosphate Injection, Bromhexine Hydrochloride Injection, Metoclopramide Hydrochloride Injection, Dihydroxypropyltheophylline Injection, Isoniazid Injection, Epinephrine Hydrochloride Injection, and Famotidine Injection, are expected to be selected in this centralized procurement.

Tianjin Pharmaceutical Group implements an integrated strategy of APIs and formulations, adhering to the concept of innovative development. It combines cost control with a stable supply chain to ensure excellent quality and reasonable profits even under centralized procurement pricing. Meanwhile, the company's significant cost advantages in APIs, production processes, and large-scale production help it leverage the centralized procurement platform to develop the market and drive the growth of its formulation business.

In the future, the company will continue to take the integrated strategy of API and formulation as the core driving force, strengthen R&D processes and scientific research projects, optimize product iteration and quality upgrades, tackle high-value projects, promote the synergistic evolution of product lines and R&D systems, and transform centralized procurement qualifications into a lasting market advantage.

Articles: Board Office of Tianjin Pharmaceutical Group Co., Ltd., China Securities Journal (China Securities Network)